Home › Funds › Soleus Capital Management, L.P. › SLN
Soleus Capital Management, L.P. position in SLN
SILENCE THERAPEUTICS PLC · Health Care
Soleus Capital Management, L.P. reported holding 2,385,700 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q3 2026 13F filing — a position valued at US$26.1M, representing 0.93% of its reported portfolio and ranking #26 among its reported holdings. Soleus Capital Management, L.P. has disclosed SLN holdings in 3 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s SLN position evolved
Soleus Capital Management, L.P. first disclosed a stake in SLN in Q3 2024 at 260,000 shares (US$4.7M). The position peaked in Q3 2026 at 2,385,700 shares, worth US$26.1M. Across 3 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,385,700 shares valued at US$26.1M — an increase of 1,755,700 shares quarter over quarter.. Notable position changes include a 279% increase in Q3 2026 (shares rose 81% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 260.00K | $4.73M | New |
| Q2 2026 | 630.00K | $6.92M | New |
| Q3 2026 | 2.39M | $26.08M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLN and 13F data
SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 45 other funds we track also report a position in SLN — the largest reported positions include Siren, L.L.C. (US$31.6M), Redmile Group, LLC (US$26.9M), TCG Crossover Management, LLC (US$19.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLN
- Siren, L.L.C. 2.89M sh · $31.56M · Q3 2026
- Redmile Group, LLC 2.46M sh · $26.90M · Q3 2026
- TCG Crossover Management, LLC 1.82M sh · $19.88M · Q3 2026
- Nextech Invest Ltd. 1.69M sh · $18.51M · Q3 2026
- KVP Capital Advisors, LP 684.12K sh · $7.48M · Q3 2026
- Tetragon Partners GP Ltd 500.00K sh · $5.46M · Q3 2026
- 5AM Venture Management, LLC 476.20K sh · $5.20M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 393.58K sh · $4.30M · Q3 2026
- Seven Fleet Capital Management LP 350.00K sh · $3.83M · Q3 2026
- Fortress Investment Group LLC 230.00K sh · $2.51M · Q3 2026
- Sofinnova Investments, Inc. 211.80K sh · $2.31M · Q3 2026
- Squadron Capital Management LLC 180.00K sh · $1.97M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held SLN?
Soleus Capital Management, L.P. has disclosed SLN holdings in 3 of the last 9 reported quarters, going back to Q3 2024.
What is Soleus Capital Management, L.P.'s current position in SLN?
As of Q3 2026, Soleus Capital Management, L.P. holds 2.39M shares of SLN (SILENCE THERAPEUTICS PLC), valued at $26.08M, representing 0.93% of its reported portfolio and ranking #26.
Has Soleus Capital Management, L.P. been buying or selling SLN?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. increased its position in SLN. The position peaked in Q3 2026 at 2.39M shares.
Which other funds hold SLN?
Other major institutional holders of SLN include Siren, L.L.C., Redmile Group, LLC, TCG Crossover Management, LLC, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.